HCAT logo

Health Catalyst, Inc. (HCAT) Hisse Analizi

Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Health Catalyst, Inc. (HCAT), Healthcare sektöründe faaliyet gösteriyor, son olarak 1.10$'dan işlem görüyor ve $80.94M piyasa değerine sahip. Hisse senedi, 9 kantitatif KPI'ya dayalı olarak orta dereceli bir derecelendirme olan 52/100 puan alıyor.

Son analiz: 9 Şub 2026
52/100 AI Puanı PD $80.94M Hacim 705.4K

Health Catalyst, Inc. (HCAT) Sağlık ve Boru Hattı Genel Bakışı

CEODaniel D. Burton
Çalışanlar1500
MerkezSouth Jordan, UT, US
Halka Arz Yılı2019
SektörHealthcare

Health Catalyst empowers healthcare organizations with cutting-edge data and analytics solutions, driving improved patient outcomes and financial performance. With a comprehensive platform and specialized services, HCAT is positioned to capitalize on the growing demand for data-driven healthcare transformation, despite current profitability challenges.

Veri Kaynağı | Finansal Veriler Kantitatif Analiz NASDAQ Analiz: 9 Şub 2026

Yatırım Tezi

Health Catalyst presents a notable research candidate within the healthcare analytics space, driven by the increasing demand for data-driven decision-making in healthcare. While the company currently operates with a negative P/E ratio of -1.41 and a negative profit margin of -34.1%, its strong gross margin of 46.5% indicates potential for future profitability as it scales its operations and achieves greater efficiency. Key growth catalysts include the expansion of its AI and data science offerings and the increasing adoption of its population health management solutions. The company's focus on providing actionable insights and automated workflows positions it to capture a significant share of the growing healthcare analytics market. Investors should monitor the company's progress in improving its financial performance and achieving profitability, with a focus on revenue growth and cost management. The company's high beta of 1.74 suggests higher volatility compared to the market.

FMP finansallarına ve nicel analizine dayanmaktadır

Temel Önemli Noktalar

  • Market Cap of $0.15B reflects its position as a smaller player in the healthcare analytics market, offering potential for growth.
  • Gross Margin of 46.5% demonstrates the value of its data and analytics platform and services.
  • P/E Ratio of -1.41 indicates that the company is currently not profitable, requiring careful monitoring of its financial performance.
  • Beta of 1.74 suggests higher volatility compared to the market, which could lead to larger gains or losses.
  • No Dividend Yield reflects the company's focus on reinvesting earnings to fund growth initiatives.

Rakipler & Benzerleri

Güçlü Yönler

  • Comprehensive data and analytics platform for healthcare.
  • Strong expertise in healthcare data and analytics.
  • Established relationships with healthcare organizations.
  • National data ecosystem for knowledge sharing.

Zayıflıklar

  • Currently unprofitable with a negative profit margin.
  • High beta indicates higher volatility.
  • Smaller market capitalization compared to larger competitors.
  • Reliance on subscription and service revenue.

Katalizörler

  • Upcoming: Expansion of AI-powered analytics capabilities to enhance clinical decision support.
  • Ongoing: Increasing adoption of the Health Catalyst data platform by healthcare systems seeking improved data insights.
  • Ongoing: Strategic partnerships with healthcare providers to implement population health management programs.
  • Upcoming: Launch of new data products and services to address emerging needs in the healthcare industry.

Riskler

  • Potential: Intense competition from larger, more established healthcare analytics providers.
  • Ongoing: The company's current unprofitability and negative profit margin pose a risk to its long-term sustainability.
  • Potential: Evolving regulatory landscape for healthcare data privacy could impact data collection and usage.
  • Potential: Economic downturn impacting healthcare spending could reduce demand for Health Catalyst's solutions.

Büyüme Fırsatları

  • Expansion of AI and Data Science Offerings: Health Catalyst can capitalize on the increasing demand for AI-powered analytics in healthcare by expanding its AI and data science offerings. This includes developing new AI algorithms and models for predictive analytics, personalized medicine, and clinical decision support. The market for AI in healthcare is projected to reach $34 billion by 2025, presenting a significant growth opportunity for Health Catalyst. Timeline: Ongoing.
  • Increased Adoption of Population Health Management Solutions: Health Catalyst can drive growth by increasing the adoption of its population health management solutions. This includes expanding its partnerships with healthcare providers and payers to implement programs that improve patient outcomes and reduce costs. The market for population health management is expected to reach $89 billion by 2027, offering a substantial growth opportunity. Timeline: Ongoing.
  • Strategic Partnerships and Acquisitions: Health Catalyst can accelerate its growth through strategic partnerships and acquisitions. This includes partnering with other healthcare technology companies to expand its product offerings and reach new markets. It can also acquire companies with complementary technologies or customer bases. Timeline: Ongoing.
  • Expansion into New Geographies: Health Catalyst can expand its geographic reach by entering new markets, both domestically and internationally. This includes targeting healthcare organizations in regions with high growth potential and limited access to advanced analytics solutions. Timeline: Ongoing.
  • Development of New Data Products and Services: Health Catalyst can drive growth by developing new data products and services that address emerging needs in the healthcare industry. This includes creating data marketplaces, providing data governance solutions, and offering data science consulting services. Timeline: Ongoing.

Fırsatlar

  • Expansion of AI and data science offerings.
  • Increased adoption of population health management solutions.
  • Strategic partnerships and acquisitions.
  • Expansion into new geographies.

Tehditler

  • Intense competition from larger healthcare analytics providers.
  • Evolving regulatory landscape for healthcare data privacy.
  • Potential for data breaches and security vulnerabilities.
  • Economic downturn impacting healthcare spending.

Rekabet Avantajları

  • Proprietary data and analytics platform designed specifically for healthcare.
  • Deep domain expertise in healthcare data and analytics.
  • Established relationships with leading healthcare organizations.
  • National data ecosystem for knowledge exchange and collaboration.

HCAT Hakkında

Health Catalyst, Inc., founded in 2008 and headquartered in South Jordan, Utah, is a leading provider of data and analytics technology and services to healthcare organizations. Originally known as HQC Holdings, Inc., the company rebranded to Health Catalyst in March 2017, reflecting its focus on catalyzing healthcare transformation through data. The company's core offering is its data and analytics platform, a commercial-grade solution designed specifically for the healthcare sector. This platform integrates with various healthcare systems to collect, process, and analyze data, providing insights that drive improvements in clinical, financial, and operational performance. Health Catalyst also offers AI and data science solutions, enabling healthcare organizations to leverage advanced analytics to improve accuracy and efficiency. Their services extend to population health management, financial transformation, and quality and safety improvement, providing healthcare providers with actionable guidance and automated workflows. Health Catalyst's national data ecosystem facilitates knowledge exchange and collaboration among healthcare organizations, fostering innovation and best practices. Despite its innovative solutions, Health Catalyst faces challenges in achieving profitability, as reflected in its negative profit margin.

Ne Yaparlar

  • Provides a data and analytics platform for healthcare organizations.
  • Offers AI and data science solutions to improve analytics accuracy.
  • Delivers population health management tools for care continuum improvement.
  • Provides financial transformation insights for costing, labor productivity, and revenue capture.
  • Offers quality and safety improvement solutions using clinical data.
  • Facilitates a national data ecosystem for knowledge exchange.

İş Modeli

  • Subscription-based revenue for access to its data and analytics platform.
  • Professional services fees for implementation, consulting, and training.
  • Revenue from AI and data science solutions.
  • Revenue from population health management services.

Sektör Bağlamı

Health Catalyst operates in the rapidly evolving healthcare information services industry, which is driven by the increasing adoption of electronic health records (EHRs), the growing demand for value-based care, and the need to improve patient outcomes and reduce costs. The market for healthcare analytics is expected to grow significantly in the coming years, driven by the increasing availability of data and the development of advanced analytics technologies. Health Catalyst competes with other healthcare analytics providers, including Cerner (now Oracle), Allscripts, and smaller, more specialized players. The company differentiates itself through its focus on providing actionable insights and automated workflows, as well as its national data ecosystem for knowledge exchange.

Kilit Müşteriler

  • Hospitals and health systems.
  • Physician groups and clinics.
  • Accountable care organizations (ACOs).
  • Health insurance payers.
AI Güveni: 71% Güncellendi: 9 Şub 2026

Finansallar

Grafik & Bilgi

Health Catalyst, Inc. (HCAT) hisse senedi fiyatı: $1.10 (+0.00, +0.00%)

Son Haberler

Analist Konsensüsü

Fikir Birliği Derecelendirmesi

HCAT için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.

Fiyat Hedefleri

HCAT için Wall Street fiyat hedefi analizi.

MoonshotScore

52/100

Bu puan ne anlama geliyor?

MoonshotScore, HCAT'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.

HCAT Hakkında Sıkça Sorulan Sorular

HCAT için değerlendirilmesi gereken temel faktörler nelerdir?

Health Catalyst, Inc. (HCAT) şu anda yapay zeka skoru 52/100, orta puanı gösteriyor. Temel güçlü yan: Comprehensive data and analytics platform for healthcare.. İzlenmesi gereken birincil risk: Potential: Intense competition from larger, more established healthcare analytics providers.. Bu bir finansal tavsiye değildir.

HCAT MoonshotScore'u nedir?

HCAT şu anda MoonshotScore'da 52/100 (Derece C) alıyor, bu da orta derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.

HCAT verileri ne sıklıkla güncellenir?

HCAT fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.

Analistler HCAT hakkında ne diyor?

HCAT için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.

HCAT'a yatırım yapmanın riskleri nelerdir?

HCAT için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Intense competition from larger, more established healthcare analytics providers.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.

HCAT'ın P/E oranı nedir?

HCAT için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için HCAT'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.

HCAT aşırı değerli mi, yoksa düşük değerli mi?

Health Catalyst, Inc. (HCAT)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.

HCAT'ın temettü verimi nedir?

Health Catalyst, Inc. (HCAT) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.

Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.

Resmi Kaynaklar

Fiyat itibarıyla Analiz güncellendi AI Puanı günlük olarak yenilenir
Veri Kaynakları ve Metodoloji
Piyasa verileri Financial Modeling Prep ve Yahoo Finance tarafından sağlanmaktadır. AI analizi Stock Expert AI tescilli algoritmaları ile yapılmaktadır. Teknik göstergeler endüstri standardı hesaplamalarla üretilmektedir. Son güncelleme: .

Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.

Analiz Notları
  • Stock data pending update, limiting complete financial analysis.
Veri Kaynakları

Popüler Hisseler